Tyler Curiel, M.D., MPH
Professor and The Daisy M. Skinner President's Chair in Cancer Immunology Research
Dr. Tyler Curiel is a physician-scientist with clinical expertise in phase I experimental therapeutics and gynecologic cancers. His laboratory expertise is in human immunology with an emphasis on understanding the immunopathologic basis of human diseases including cancer, infections and autoimmunity.
He has significant administrative expertise as past chief of two different academic divisions of hematology and medical oncology, director of a general clinical research center and executive director of an NCI-designated cancer center. He translates his groups discoveries into novel clinical trials.
Publications
Journal Article |
| Curiel TJ. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model Experimental Gerontology 2018 Jan;105:146-154. |
| Ellen Kraig, Leslie A. Linehan, Hanyu Liang, Terry Q. Romo, Qianqian Liu, Yubo Wu, Adriana D. Benavides, Tyler J. Curiel, Martin A. Javors, Nicolas Musi, Laura Chiodo, Wouter Koek, Jonathan A.L. Gelfond, Dean L. Kellogg. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects Experimental Gerontology 2018 Jan;105:53-69. |
| Zhang X., Huai-Chin Chiang, Yao Wang, Chi Zhang, Sabrina Smith, Xiayan Zhao, Sreejith Nair, Joel Michalek, Ismail Jatoi, Meeghan Lautner, Boyce Oliver, Howard Wang, Anna Petit, M Teresa Soler Monso, Joan Brunet, Francesca Mateo, Miguel Pujana, Elizabeth Poggi, Krysta Chaldekas, Claudine Isaacs, Beth Peshkin, Oscar Ochoa, Frederic Che'din, Constantine Theoharis, Lu-Zhe Sun, Tyler Curiel, Richard Elledge, Victor Jin, Yanfen Hu, and Rong Li. Attenuation of RNA Polymerase II Pausing Mitigates BRCA1-Associated R-loop Accumulation and Tumorigenesis Nat Commun 2017 Jun;26(8). |
| Curiel TJ. Tumor cell-intrinsic PD-L1: a novel metabolic balancing act with clinical potential Autophagy 2017 Jan;13(5):987-988. |
| Curiel TJ. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target Clinical Cancer Research 2017 Jan;23:441-453. |
| Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts Clinical & Experimental Immunology 2017 Jan;187:53-63. |
| Curiel TJ. Biphasic rapamycin effects in lymphoma and carcinoma treatment Cancer Research 2017 Jan;77:520-531. |
| Curiel TJ. Acquired resistance to BRAF inhibitors restores immunosuppressive myeloid cells that impair immunotherapy against autochthonous mouse melanoma Cancer Research 2017 Jan;77:1599-1610. |
| Curiel TJ. Characterization of tumor-driven Th17-to-Treg cell transdifferentiation Nature Communications 2017 Jan;8. |
| Curiel TJ. Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice Journal of Biological Chemistry 2017 Jan;293(8):2841-2849. |
| Curiel TJ. Tumor cell-independent estrogen signaling drives progression through mobilization of myeloid-derived suppressor cells Cancer Discovery 2017 Jan;7:72-85. |
| Curiel TJ. Tumor intrinsic PD-L1 promotes tumor initiating cell generation and functions Signal Transduction and Targeted Therapy 2016 Jan;. |
| Curiel TJ. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma Cancer Research 2016 Jan;76:6964-6974. |
| Curiel TJ. Immune stimulatory effects of rapamycin are mediated by stimulation of antitumor γδ T cells Cancer Research 2016 Jan;76:5970-5982. |
| Curiel TJ. Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer Oncotarget 2016 Jan;7:42585-42597. |
| Curiel TJ. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-PD-L1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer Journal of Clinical Oncology 2016 Jan;34:3119-3125. |
| Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela J, Galvan V, Padron A, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid and innate lymphoid cells and gut flora and prolongs life of immune deficient mice. (In Press) Aging Cell 2015 Jan;14(6):945-956. |
| Curiel TJ. Immunotherapy for Ovarian Cancer Current Treatment Options in Oncology 2015 Jan;. |
| Curiel TJ. Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial Clinical Cancer Research 2015 Jan;21:303-311. |
| Curiel TJ. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 2015 Jan;14:497-510. |
| Curiel TJ. Host miR-155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism Cancer Research 2015 Jan;75:519-531. |
| Curiel TJ. Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage Cancer Prevention Research 2015 Jan;8:400-409. |
| Messer JC, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis Urology 2014 Apr;83:863-867. |
| Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. PMID 15313886 Cancer Res 2004 Aug;64(16):5535-5538. |
Grants
Scroll table right to view more
Federal |
|
| Funding Agency | |
| Title | NCI (PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration |
| Status | Active |
| Period | 4/2017 - 3/2022 |
| Role | Co-Investigator |
| Grant Detail | Council Meeting Date: 2017/01 Meeting Date: 11/15/201 |
| Funding Agency | |
| Title | NCI ?B7-H1 signals in ovarian cancer? |
| Status | Active |
| Period | 9/2012 - 6/2017 |
| Role | Principal Investigator |
| Grant Detail | |
| Funding Agency | Clayton Foundation |
| Title | ?Targeting novel tumor-intrinsic PD-L1/PD-1 pathways to optimize cancer immunotherapy? |
| Status | Active |
| Period | 3/2018 - 12/2023 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | Tumor intrinsic B7-H1 in cancer pathogenesis |
| Status | Active |
| Period | 4/2016 - 3/2022 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | NCI ?Regulation of ER-beta signaling in carcinogenesis? |
| Status | Active |
| Period | 2/2017 - 1/2022 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Cancer Therapy and Research Center |
| Title | Role: Leader, Experimental and Developmental Therapeutics |
| Status | Active |
| Period | 8/2015 - 7/2020 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | Immune effects of rapamycin in cancer prevention |
| Status | Active |
| Period | 6/2014 - 5/2020 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | NIH ?San Antonio Claude D. Pepper Older Americans Independence Center |
| Status | Active |
| Period | 6/2015 - 5/2020 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | CPRIT Gut integrin signals direct IL-18 in colon carcinogenesis |
| Status | Active |
| Period | 5/2016 - 4/2019 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | ?Gut integrin signals direct IL-18 in colon carcinogenesis? |
| Status | Active |
| Period | 5/2016 - 4/2019 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Ovarian Cancer Research Fund |
| Title | ?Rational design of effective multi-modal ovarian cancer immunotherapy? |
| Status | Active |
| Period | 1/2014 - 12/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | ?Phase I trial of anti-PD-L1 antibody in selected solid tumors? |
| Status | Active |
| Period | 11/2012 - 11/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | CDMRP ?Novel B7-H1 immune co-signaling effects on estrogens in lupus? |
| Status | Active |
| Period | 7/2014 - 9/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | CDMRP ?Testing ER-beta agonist synergy with B7-H1 and mTOR inhibitors as novel and effective treatments for ovarian cancer? |
| Status | Active |
| Period | 5/2015 - 7/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | CDMRP ?Novel Listeria vectors secreting gut flora-altering agents to prevent colon cancer and treat colitis? |
| Status | Active |
| Period | 5/2015 - 7/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | Rational design of effective multi-modal ovarian cancer immunotherapy Ovarian Cancer Research Fund |
| Status | Active |
| Period | 1/2014 - 1/2018 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | Development of very promising fully human therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers? |
| Status | Active |
| Period | 11/2013 - 8/2017 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | |
| Title | Improving efficacy of BCG for bladder cancer |
| Status | Active |
| Period | 7/2013 - 6/2017 |
| Role | Co-Investigator |
| Grant Detail | |
Education
Scroll table right to view more
| Year | Degree | Discipline | Institution |
| 1983 | MPH | Epidemiology/Biostatistics | Harvard University Boston , MA |
| 1982 | MD | Medicine | Duke Medical School Durham , NC |
| 1977 | BS | Chemistry (summa cum laude, with highest honors, with honors in chemistry) | University of Georgia Athens , GA |
| Postdoctoral Fellowship | Medicine | Harvard Medical School Boston , MA |
|
| Postdoctoral Fellowship | Infectious Disease | Harvard Medical School & Massachusetts General Hospital Boston , MA |
|
| Residency | Internal Medicine | Yale Medical School & Yale-New Haven Hospital New Haven , CT |
|
| Postdoctoral Fellowship | Medical Oncology | University of Colorado Health Sciences Center Denver , CO |
|
| Internship | Medicine | Yale Medical School & Yale-New Haven Hospital New Haven , CT |